公开(公告)号：US20190192553A1

公开(公告)日：2019-06-27

申请号：US16094300

申请日：2017-04-12

Applicant: BIOIBERICA, S.A.U.

Inventor： José ESCAICH FERRER ,  Sergi SEGARRA LÓPEZ ,  Javier CÓRDOBA LUCIO ,  Jorge FLORES GARCÍA ,  Alfonso VELASCO FRANCO

IPC: A61K31/728 ,  A61K31/737 ,  A61K31/202 ,  A61P17/06 ,  A61P17/02 ,  A61K9/48 ,  A23L33/115

CPC classification number: A61K31/728 ,  A23L33/115 ,  A23V2002/00 ,  A23V2200/318 ,  A23V2250/1872 ,  A23V2250/1874 ,  A23V2250/1882 ,  A23V2250/51 ,  A61K9/4825 ,  A61K31/01 ,  A61K31/202 ,  A61K31/52 ,  A61K31/726 ,  A61K31/737 ,  A61P17/02 ,  A61P17/06

Abstract: The present invention relates to a composition comprising hyaluronic acid, dermatan sulfate, at least one omega-3 fatty acid, and at least one nucleotide. It also relates to the new composition for use in the treatment or prevention of diseases, ailments, dysfunctions, or alterations of the skin, preferably atopic dermatitis. The composition may be in the form of a pharmaceutical composition, food supplement, functional food, or medical food.

公开(公告)号：US20170000181A1

公开(公告)日：2017-01-05

申请号：US15039910

申请日：2014-11-27

Applicant: NESTEC S.A.

Inventor： Peter Erdmann ,  Frederic Destaillats ,  Delphine Egli ,  Florence Blancher ,  Catherine Mace ,  Sagar Thakkar ,  Francesca Giuffrida ,  Yassaman Shahkhalili Dulloo

IPC: A23L33/17 ,  A23L33/00

CPC classification number: A23L33/17 ,  A23L33/30 ,  A23L33/40 ,  A23V2002/00 ,  A23V2250/0612 ,  A23V2250/0624 ,  A23V2250/0626 ,  A23V2250/0638 ,  A23V2250/0644 ,  A23V2250/065 ,  A23V2250/1578 ,  A23V2250/1588 ,  A23V2250/1592 ,  A23V2250/1598 ,  A23V2250/16 ,  A23V2250/161 ,  A23V2250/1612 ,  A23V2250/1614 ,  A23V2250/1626 ,  A23V2250/1642 ,  A23V2250/1868 ,  A23V2250/1872 ,  A23V2250/1874 ,  A23V2250/304 ,  A23V2250/702 ,  A23V2250/7042 ,  A23V2250/7044 ,  A23V2250/7046 ,  A23V2250/7052 ,  A23V2250/7056 ,  A23V2250/706 ,  A23V2250/708 ,  A23V2250/71 ,  A23V2250/712 ,  A23V2250/7142 ,  A23V2250/72

Abstract: The present invention relates to an age-tailored nutritional composition system comprising at least one nutritional composition A that is administered to an infant from birth and until 3-6 months of life of said infant, at least one nutritional composition B that is administered to an infant from 3-6 months and until 1 year of life of said infant, at least one nutritional composition C that is administered after the first year of life of the young child, and wherein the amount of protein of the different nutritional compositions A, B, C decreases with the sequence of administration. The present invention furthermore relates to the uses of said nutritional composition system.

Abstract translation: 本发明涉及一种年龄定制的营养组合物系统，其包含至少一种营养组合物A，所述营养组合物A从所述婴儿的出生和3-6个月的生命期间施用于婴儿，至少一种营养组合物B被施用于 所述婴儿的3-6个月至1岁的婴儿，至少一种营养组合物C，其在所述幼儿的第一年后施用，并且其中所述不同营养组合物A，B的蛋白质的量 C随着给药顺序降低。 本发明还涉及所述营养组合物系统的用途。

公开(公告)号：US20150174080A1

公开(公告)日：2015-06-25

申请号：US14414760

申请日：2013-07-30

Applicant: NESTEC S.A.

Inventor： Eduardo Schiffrin ,  Viral Brahmbhatt ,  Francois-Pierre Martin ,  Jalil Benyacoub

IPC: A61K31/122 ,  A61K31/59 ,  A61K31/20 ,  A61K45/06 ,  A61K33/00 ,  A61K33/42 ,  A61K33/06 ,  A61K33/20 ,  A61K33/26 ,  A61K33/30 ,  A61K33/34 ,  A61K33/32 ,  A61K33/16 ,  A61K33/24 ,  A61K33/04 ,  A61K33/18 ,  A61K31/07 ,  A61K31/015 ,  A61K31/355 ,  A61K31/375 ,  A61K31/51 ,  A61K31/525 ,  A61K31/197 ,  A61K31/4415 ,  A61K31/714 ,  A61K31/455 ,  A61K31/519 ,  A61K31/4188 ,  A61K31/14 ,  A23L1/302 ,  A23L1/303 ,  A23L1/305 ,  A23L1/30 ,  A23L1/304 ,  A23L1/308 ,  A23L1/27 ,  A23L2/38 ,  A23L2/66 ,  A61K38/17

CPC classification number: A61K31/122 ,  A23L2/38 ,  A23L2/66 ,  A23L5/40 ,  A23L33/10 ,  A23L33/12 ,  A23L33/135 ,  A23L33/15 ,  A23L33/155 ,  A23L33/16 ,  A23L33/175 ,  A23L33/19 ,  A23L33/21 ,  A23L33/30 ,  A23L33/40 ,  A23V2002/00 ,  A23V2200/00 ,  A61K31/015 ,  A61K31/07 ,  A61K31/14 ,  A61K31/197 ,  A61K31/20 ,  A61K31/202 ,  A61K31/355 ,  A61K31/375 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/519 ,  A61K31/525 ,  A61K31/59 ,  A61K31/714 ,  A61K33/00 ,  A61K33/04 ,  A61K33/06 ,  A61K33/16 ,  A61K33/18 ,  A61K33/20 ,  A61K33/24 ,  A61K33/26 ,  A61K33/30 ,  A61K33/32 ,  A61K33/34 ,  A61K33/42 ,  A61K38/1709 ,  A61K45/06 ,  A23V2200/32 ,  A23V2250/1578 ,  A23V2250/1582 ,  A23V2250/1586 ,  A23V2250/1588 ,  A23V2250/159 ,  A23V2250/1592 ,  A23V2250/1598 ,  A23V2250/16 ,  A23V2250/1608 ,  A23V2250/161 ,  A23V2250/1612 ,  A23V2250/1614 ,  A23V2250/1618 ,  A23V2250/1626 ,  A23V2250/1642 ,  A23V2250/1872 ,  A23V2250/1874 ,  A23V2250/1878 ,  A23V2250/1882 ,  A23V2250/54246 ,  A23V2250/702 ,  A23V2250/7042 ,  A23V2250/7044 ,  A23V2250/7046 ,  A23V2250/705 ,  A23V2250/7052 ,  A23V2250/7056 ,  A23V2250/708 ,  A23V2250/71 ,  A23V2250/712 ,  A23V2250/7142 ,  A23V2250/7144 ,  A23V2250/72

Abstract: A nutritional composition for promoting musculoskeletal health in patients with inflammatory bowel disease is disclosed. The nutritional composition comprises casein protein, vitamin K in a ratio of vitamin K1:vitamin K2 being between 3:1 to 1:3 and the vitamin K providing between 3.5-20 μg/100 kcal of the nutritional composition, vitamin D and alpha-linolenic acid. A pharmaceutical formulation, a nutritional formulation, a tube-feed formulation, a dietary supplement, a functional food, a beverage product or a combination thereof comprising the nutritional composition is also disclosed. A method for improving musculoskeletal health is also disclosed.

Abstract translation: 公开了一种用于促进炎症性肠病患者肌肉骨骼健康的营养组合物。 营养组合物包含酪蛋白，维生素K与维生素K 3的比例在3:1至1:3之间的维生素K，维生素K提供3.5-20μg/ 100kcal的营养组合物，维生素D和α- 亚麻酸。 还公开了包含营养组合物的药物制剂，营养制剂，管饲料制剂，膳食补充剂，功能性食品，饮料产品或其组合。 还公开了一种改善肌肉骨骼健康的方法。

公开(公告)号：US20150173410A1

公开(公告)日：2015-06-25

申请号：US14577872

申请日：2014-12-19

Applicant: Change Cola, Inc.

Inventor： James PHILLIPS ,  Kevin CONWAY

IPC: A23L2/54 ,  A23L1/30

CPC classification number: A23L2/54 ,  A23L2/52 ,  A23L33/12 ,  A23L33/20 ,  A23P10/30 ,  A23V2002/00 ,  A23V2200/332 ,  A23V2250/1868 ,  A23V2250/187 ,  A23V2250/1872 ,  A23V2250/1874 ,  A23V2250/188

Abstract: Provided herein are drinks (e.g., carbonated drinks) comprising one or more unsaturated fatty acids (e.g., an omega-3, omega-6, and/or omega-9) fatty acids, wherein the drinks are characterized by a low glycemic index and/or an enhanced non-refrigerated shelf life.

Abstract translation: 本文提供了包含一种或多种不饱和脂肪酸（例如，ω-3，ω-6和/或ω-9）脂肪酸的饮料（例如，碳酸饮料），其中所述饮料的特征在于低血糖指数和 /或增强的非冷藏保质期。

公开(公告)号：US08871808B2

公开(公告)日：2014-10-28

申请号：US11919006

申请日：2007-06-21

Applicant: Zvi Cohen ,  Inne Khozin-Goldberg ,  Sammy Boussiba ,  Avigad Vonshak

Inventor： Zvi Cohen ,  Inne Khozin-Goldberg ,  Sammy Boussiba ,  Avigad Vonshak

IPC: A01N37/00 ,  C12P7/64 ,  C12N1/12 ,  A23D9/00 ,  C12N9/02 ,  A23L1/29 ,  A23L1/30 ,  C12R1/89

CPC classification number: A23D9/00 ,  A23L33/12 ,  A23L33/40 ,  A23V2002/00 ,  C12N9/0083 ,  C12P7/6472 ,  C12R1/89 ,  A23V2250/1874 ,  A23V2200/334 ,  A23V2250/1862

Abstract: The present invention is primarily directed to a mutant strain of Parietochloris incisa, characterized in comprising a substantially reduced intracellular concentration of arachidonic acid (AA) together with a substantially increased intracellular concentration of dihomo-gamma-linolenic acid 20:3ω6 (DGLA).

Abstract translation: 本发明主要针对Parietochloris incisa的突变菌株，其特征在于包含基本上降低的花生四烯酸（AA）的细胞内浓度以及二氢-γ-亚麻酸20:3ω6（DGLA）的细胞内浓度的显着增加。

公开(公告)号：US08759319B2

公开(公告)日：2014-06-24

申请号：US13620382

申请日：2012-09-14

Applicant: Robert Johan Joseph Hageman ,  Eline Marleen Van Der Beek ,  Martine Groenendijk ,  Patrick Joseph Gerardus Hendrikus Kamphuis

Inventor： Robert Johan Joseph Hageman ,  Eline Marleen Van Der Beek ,  Martine Groenendijk ,  Patrick Joseph Gerardus Hendrikus Kamphuis

IPC: A01N43/04 ,  A61K31/70

CPC classification number: A23L2/52 ,  A23L33/115 ,  A23L33/12 ,  A23L33/40 ,  A23V2002/00 ,  A61K31/19 ,  A61K31/201 ,  A61K31/202 ,  A61K2300/00 ,  A23V2250/187 ,  A23V2250/1868 ,  A23V2250/1874 ,  A23V2250/1882 ,  A23V2250/28 ,  A23V2250/54246 ,  A23V2250/704 ,  A23V2250/7056 ,  A23V2250/70 ,  A23V2250/156

Abstract: The invention pertains to the use of a lipid fraction for the support of brain function. The lipid fraction comprises the medium-chain fatty acids at least 4 g hexanoic acid and/or at least 5 g octanoic acid, at least 1 g eicosapentaenoic acid, and in addition more than 0.4 g α-linolenic acid per 100 g fatty acids of the lipid fraction.

Abstract translation: 本发明涉及用于支持脑功能的脂质部分。 脂质部分包含中链脂肪酸至少4g己酸和/或至少5g辛酸，至少1g二十碳五烯酸，并且还包含多于0.4gα-亚麻酸/ 100g脂肪酸 脂质分数。

公开(公告)号：US08729123B2

公开(公告)日：2014-05-20

申请号：US13251399

申请日：2011-10-03

Applicant: Bernd Stahl ,  Gunther Boehm ,  Christopher Beermann ,  Johan Garssen

Inventor： Bernd Stahl ,  Gunther Boehm ,  Christopher Beermann ,  Johan Garssen

IPC: A61K31/22 ,  A61K31/20

CPC classification number: A61K31/202 ,  A23L33/12 ,  A23L33/22 ,  A23L33/40 ,  A23V2002/00 ,  A23V2250/187 ,  A23V2250/1868 ,  A23V2250/5046 ,  A23V2250/1872 ,  A23V2250/1874 ,  A23V2250/0644 ,  A23V2250/1642

Abstract: The invention relates to the use of long chain polyunsaturated fatty acids for the manufacture of a nutritional composition for feeding infants of a mother who suffered from a metabolic disorder during pregnancy and to a corresponding composition. Said composition comprises a n-3 polyunsaturated fatty acid fraction containing at least 0.1 wt % docosahexaenoic acid (DHA) based on total weight of the lipid, at least 0.01 wt % n-3 docosapentaenoic acid (DPAn-3) based on total weight of the lipid, and at least 0.01 wt. % eicosapentaenoic acid (EPA) based on total weight of the lipid, wherein the sum of DHA, DPAn-3 and EPA is below 1 wt. % of total lipid.

Abstract translation: 本发明涉及长链多不饱和脂肪酸用于制造用于喂养怀孕期间代谢紊乱的母亲的婴儿的营养组合物和相应组合物的用途。 所述组合物包含n-3多不饱和脂肪酸级分，其含有基于脂质总重量的至少0.1重量％二十二碳六烯酸（DHA），至少0.01重量％的n-3二十二碳五烯酸（DPAn-3），基于 脂质和至少0.01重量％ 基于脂质总重量的二十碳五烯酸（EPA），其中DHA，DPAn-3和EPA的总和低于1wt。 总脂质的百分比。

公开(公告)号：US20140017219A1

公开(公告)日：2014-01-16

申请号：US14032101

申请日：2013-09-19

Applicant: Nitromega Corp.

Inventor： Raymond A. Miller

IPC: A61K31/202 ,  A61K31/714 ,  A61K45/06 ,  A61K36/16 ,  A61K36/258 ,  A61K31/122 ,  A61K31/355 ,  A61K31/519

CPC classification number: A61K31/202 ,  A23L33/12 ,  A23L33/15 ,  A23V2002/00 ,  A61K9/4858 ,  A61K31/122 ,  A61K31/201 ,  A61K31/355 ,  A61K31/519 ,  A61K31/557 ,  A61K31/714 ,  A61K36/16 ,  A61K36/258 ,  A61K45/06 ,  A61K2300/00 ,  A23V2200/322 ,  A23V2250/1868 ,  A23V2250/187 ,  A23V2250/1874 ,  A23V2250/188 ,  A23V2250/2122 ,  A23V2250/2124 ,  A23V2250/7056 ,  A23V2250/706 ,  A23V2250/712

Abstract: A composition for treating, ameliorating and/or preventing conditions associated with cognitive decline and/or motor neuron death comprise a fatty acid component enriched for one or more activated fatty acids and a nutraceutically acceptable excipient. A method for treating, ameliorating and/or preventing conditions associated with cognitive decline and/or motor neuron death includes administering a fatty acid component enriched for one or more activated fatty acids.

Abstract translation: 用于治疗，改善和/或预防与认知衰退和/或运动神经元死亡相关的病症的组合物包含富含一种或多种活性脂肪酸的脂肪酸组分和营养药学上可接受的赋形剂。 用于治疗，改善和/或预防与认知衰退和/或运动神经元死亡相关的病症的方法包括给予富含一种或多种活化脂肪酸的脂肪酸组分。

公开(公告)号：US20130296428A1

公开(公告)日：2013-11-07

申请号：US13859011

申请日：2013-04-09

Applicant: Nestec S.A.

Inventor： Catherine Mace ,  Olivier Aprikian

IPC: A61K31/202 ,  A23L1/29

CPC classification number: A61K31/202 ,  A23L33/12 ,  A23L33/40 ,  A23V2002/00 ,  A23V2200/30 ,  A23V2200/332 ,  A23V2250/0624 ,  A23V2250/156 ,  A23V2250/1862 ,  A23V2250/1868 ,  A23V2250/1872 ,  A23V2250/1874 ,  A23V2250/1882 ,  A23V2250/5424 ,  A23V2250/54246 ,  A23V2250/70

Abstract: A nutritional composition comprising a significant amount of arachidonic acid (ARA) is described. Such nutritional composition is particularly suitable for infants below the age of 3 years, preferably between birth and 12 months of life. The composition can be used to reduce the risk of developing overweight/obesity and/or insulin resistance later in life.

Abstract translation: 描述了包含大量花生四烯酸（ARA）的营养组合物。 这种营养组合物特别适用于3岁以下的婴儿，优选在出生至12个月之间的婴儿。 该组合物可用于降低在生命后期发展超重/肥胖和/或胰岛素抵抗的风险。

公开(公告)号：US20130295179A1

公开(公告)日：2013-11-07

申请号：US13862179

申请日：2013-04-12

Applicant: Christian TERREAUX ,  Eleonora HOMBERGER ,  Burkhard KRIWET ,  Eduardo BARRAGAN PEREZ

Inventor： Christian TERREAUX ,  Eleonora HOMBERGER ,  Burkhard KRIWET ,  Eduardo BARRAGAN PEREZ

IPC: A61K31/202 ,  A61K33/26 ,  A61K33/30 ,  A61K31/4458 ,  A61K45/06

CPC classification number: A61K31/202 ,  A23L33/105 ,  A23L33/12 ,  A23L33/15 ,  A23L33/155 ,  A23L33/16 ,  A23V2002/00 ,  A61K31/355 ,  A61K31/4415 ,  A61K31/4458 ,  A61K31/519 ,  A61K31/59 ,  A61K31/675 ,  A61K31/714 ,  A61K33/26 ,  A61K33/30 ,  A61K45/06 ,  A61K2300/00 ,  A23V2200/322 ,  A23V2250/156 ,  A23V2250/1626 ,  A23V2250/1642 ,  A23V2250/1868 ,  A23V2250/187 ,  A23V2250/1874 ,  A23V2250/2132 ,  A23V2250/70

Abstract: The present application relates to compositions for use in a method of treating and/or preventing mental and behavioral disorders and/or improving mental health and cognitive functions in a subject, comprising: a) Docosahexaenoic acid (DHA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; b) Eicosapentaenoic acid (EPA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; c) γ-linolenic acid (GLA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; and at least a psychostimulant compound selected among methylphenidate HCl, atomoxetine, amphetamine, gamma-hydroxybutyrate, dextroamphetamine, sibutramine, methylenedioxymethamphetamine, and/or an anxiolytic compound selected among fluoxatine, sertraline, paroxetine, fluoroxamine, citralopram, venlafaxine, bupropion, nefazodone, and mirtazapine. The present application also relates to the method of treating and/or preventing mental and behavioral disorders and/or improving mental health and cognitive functions in a subject, comprising administering an effective amount of a composition comprising: a) Docosahexaenoic acid (DHA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; b) Eicosapentaenoic acid (EPA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; c) γ-linolenic acid (GLA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; and at least a psychostimulant compound selected among methylphenidate HCl, atomoxetine, amphetamine, gamma-hydroxybutyrate, dextroamphetamine, sibutramine, methylenedioxymethamphetamine, and/or an anxiolytic compound selected among fluoxatine, sertraline, paroxetine, fluoroxamine, citralopram, venlafaxine, bupropion, nefazodone, and mirtazapine.